Further experiences with tacrolimus and bone marrow augmentation in renal transplant patients.
This chapter will serve to update last year's report, published in SURGICAL TECHNOLOGY INTERNATIONAL III and will discuss our experience at the University of Pittsburgh with the use of tacrolimus as the primary immunosuppressive agent after renal transplantation, and our program of combined kidney-bone marrow transplantation to augment chimerism.